Business Description
Novonesis (Novozymes) B
NAICS : 325411
ISIN : DK0060336014
Share Class Description:
NVZMF: Class BCompare
Compare
Traded in other countries / regions
NSIS B.Denmark0Q4U.UKNVZMY.USANZM2.GermanyNZYM.AustriaNZYM.Mexico IPO Date
2009-09-14Description
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.13 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.18 | |||||
| Debt-to-EBITDA | 3.48 | |||||
| Interest Coverage | 34.62 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 4.88 | |||||
| Beneish M-Score | -1.03 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 9.1 | |||||
| 3-Year EBITDA Growth Rate | 4.7 | |||||
| 3-Year EPS without NRI Growth Rate | 7.4 | |||||
| 3-Year FCF Growth Rate | -14.6 | |||||
| 3-Year Book Growth Rate | 7.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 11.82 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 16.66 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 46.58 | |||||
| 9-Day RSI | 46.79 | |||||
| 14-Day RSI | 44.85 | |||||
| 3-1 Month Momentum % | -10.28 | |||||
| 6-1 Month Momentum % | -0.77 | |||||
| 12-1 Month Momentum % | 17.58 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.11 | |||||
| Quick Ratio | 0.69 | |||||
| Cash Ratio | 0.16 | |||||
| Days Inventory | 184.73 | |||||
| Days Sales Outstanding | 81.84 | |||||
| Days Payable | 77.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.99 | |||||
| Dividend Payout Ratio | 0.35 | |||||
| 3-Year Dividend Growth Rate | 25.1 | |||||
| Forward Dividend Yield % | 2 | |||||
| 5-Year Yield-on-Cost % | 1.85 | |||||
| 3-Year Average Share Buyback Ratio | 0.2 | |||||
| Shareholder Yield % | -2.04 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 54.32 | |||||
| Operating Margin % | 24.94 | |||||
| Net Margin % | 16.89 | |||||
| FCF Margin % | 11.69 | |||||
| ROE % | 9.78 | |||||
| ROA % | 6.09 | |||||
| ROIC % | 7.68 | |||||
| 3-Year ROIIC % | 7.86 | |||||
| ROC (Joel Greenblatt) % | 24.14 | |||||
| ROCE % | 10.27 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 38.23 | |||||
| Forward PE Ratio | 33.32 | |||||
| PE Ratio without NRI | 34.15 | |||||
| Price-to-Owner-Earnings | 212.7 | |||||
| PEG Ratio | 8.13 | |||||
| PS Ratio | 6.46 | |||||
| PB Ratio | 2.36 | |||||
| Price-to-Tangible-Book | 34.73 | |||||
| Price-to-Free-Cash-Flow | 55.17 | |||||
| Price-to-Operating-Cash-Flow | 27.85 | |||||
| EV-to-EBIT | 48.33 | |||||
| EV-to-Forward-EBIT | 27.51 | |||||
| EV-to-EBITDA | 48.33 | |||||
| EV-to-Forward-EBITDA | 20.52 | |||||
| EV-to-Revenue | 11.51 | |||||
| EV-to-Forward-Revenue | 6.45 | |||||
| EV-to-FCF | 98.31 | |||||
| Price-to-GF-Value | 0.83 | |||||
| Price-to-Projected-FCF | 2.13 | |||||
| Price-to-DCF (Earnings Based) | 2.42 | |||||
| Price-to-DCF (FCF Based) | 3.91 | |||||
| Price-to-Median-PS-Value | 1.84 | |||||
| Price-to-Graham-Number | 8.18 | |||||
| Earnings Yield (Greenblatt) % | 2.07 | |||||
| FCF Yield % | 1.08 | |||||
| Forward Rate of Return (Yacktman) % | 3.18 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:NVZMF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Novonesis (Novozymes) B Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2,595.926 | ||
| EPS (TTM) ($) | 1.575 | ||
| Beta | 1.17 | ||
| 3-Year Sharpe Ratio | -0.28 | ||
| 3-Year Sortino Ratio | -0.36 | ||
| Volatility % | 22.86 | ||
| 14-Day RSI | 44.85 | ||
| 14-Day ATR ($) | 1.020467 | ||
| 20-Day SMA ($) | 57.52965 | ||
| 12-1 Month Momentum % | 17.58 | ||
| 52-Week Range ($) | 49.89 - 71.518 | ||
| Shares Outstanding (Mil) | 464.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Novonesis (Novozymes) B Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Novonesis (Novozymes) B Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Novonesis (Novozymes) B Frequently Asked Questions
What is Novonesis (Novozymes) B(NVZMF)'s stock price today?
The current price of NVZMF is $57.90. The 52 week high of NVZMF is $71.52 and 52 week low is $49.89.
When is next earnings date of Novonesis (Novozymes) B(NVZMF)?
The next earnings date of Novonesis (Novozymes) B(NVZMF) is 2025-02-26.
Does Novonesis (Novozymes) B(NVZMF) pay dividends? If so, how much?
The Dividend Yield %  of Novonesis (Novozymes) B(NVZMF) is 0.99% (As of Today), Highest Dividend Payout Ratio of Novonesis (Novozymes) B(NVZMF) was 0.84. The lowest was 0.31. And the median was 0.43. The  Forward Dividend Yield % of Novonesis (Novozymes) B(NVZMF) is 2%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers